Elicera Therapeutics (STO:ELIC) Is In A Strong Position To Grow Its Business
Aug 26
ELIC Share Price Performance
SEK 6.49
4.39 (209.05%)
Price SEK 6.49
Share PriceSEK 6.49
ELIC Community Narratives
There are no narratives available yet.
Recent ELIC News & Updates
Elicera Therapeutics AB (publ) Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 29, 2025
- Earnings per share (EPS)
- -0.39
- Gross Margin
- 100.00%
- Net Profit Margin
- -434.92%
- Debt/Equity Ratio
- 0%
Elicera Therapeutics AB (publ) Competitors
Snowflake Analysis
About ELIC
- Founded
- 2014
- Employees
- 2
- CEO
- WebsiteView website
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden.
Market Insight
Market sentiment on BTC treasury companies is moving, and with volatility rising, disagreements over their future prospects are as heated as ever.
Continue reading
Swedish Market Performance
- 7 Days: -0.04%
- 3 Months: 3.9%
- 1 Year: -0.4%
- Year to Date: 2.2%
The Energy sector gained 61% while the market remained flat over the last week. Similarly, the market is flat for the past 12 months. Looking forward, earnings are forecast to grow by 17% annually. Market details ›